AQST (AQST) Stock Analysis
Verdict: HOLD
Severe cash burn and $131.4M debt create solvency pressure while binary pipeline catalysts for AQST-109 dictate the company's valuation.
Investment score: 44/100
Is AQST Stock Worth Reviewing? AI Model Thesis
The model score of 44/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| ACRS | -8.88 | 5.90 | 87.51 | -9.32 | — | -9.21 |
| COLL | 14.73 | 2.34 | 0.90 | 2.49 | — | 0.06 |
| CRMD | 3.26 | 1.34 | 1.33 | 2.02 | — | 0.40 |
| PHAT | -5.70 | -1.78 | 2.46 | -16.37 | — | -0.41 |
Should You Buy or Sell AQST Stock? Model Reasoning
The model score of 44/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
AQST Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Anaphylm (AQST-109) achieves FDA approval by 2027 without clinical holds or Complete Response Letters (CRLs).","Annual operating cash burn remains below $60M, providing ~24 months of runway with existing $121.17M cash.","Share dilution slows down following the share count doubling from 61.26M (2023) to 121.97M (2025)."]
AQST Risk & Opportunity Analysis
Key Investment Risks
- Elevated Debt Burden ($131.45M) and Deficit Shareholder Equity — If pipeline commercialization is delayed, high fixed debt service costs could force aggressive equity dilution or restructuring given negative total equity (-$33.66M).
- Deteriorating Core Revenue (-22.56% YoY in 2025) and Broadening Net Losses (-$83.78M) — Continued shrinkage of commercial product sales increases reliance on capital markets, driving net operating losses deeper into negative territory.
- Binary Regulatory and Clinical Trial Failures — A Complete Response Letter (CRL) or negative Phase 3 trial data for AQST-109 would eliminate the primary bull catalyst, sending shares down toward the 52-week low of $2.93.
- Unilateral Insider Selling (15 Sells, 0 Buys) — Consistent insider selling suggests management views current equity pricing as full relative to near-term risk-adjusted execution.
Growth Opportunities & Upside Drivers
- AQST-109 (Anaphylaxis Film) Pipeline Opportunity — If approved by the FDA, AQST-109 would provide a needle-free oral film alternative to epinephrine autoinjectors, targeting a multi-billion dollar emergency allergy market and accelerating revenue toward consensus 2029 estimates of $190M.
- Proprietary PharmFilm Platform Monopolization — Patented delivery technology allows AQST to license out reformulated existing drugs, generating high gross margin (67.04%) product streams that help subsidize R&D.
- Sufficient Short-Term Liquidity Buffer — Cash reserves of $121.17M as of year-end 2025 yield a current ratio of 7.19x, providing roughly 27 months of operational runway based on 2025 free cash flow burn (-$52.99M).
- Unanimous Wall Street Analyst Price Targets — 14 out of 15 covering analysts recommend Buy/Strong Buy with an average price target of $11.00, representing 135% potential upside if clinical milestones are met.
AQST Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About AQST (AQST)
Is AQST stock a good investment?
The cached TradeMates AI model rates AQST as HOLD with an investment score of 44/100. The model score of 44/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Does AQST pay a dividend?
The cached stock data on this page does not show a positive dividend yield for AQST. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does AQST stock do?
Specialty pharmaceutical company focused on developing and commercializing proprietary oral film formulations (PharmFilm) while advancing late-stage clinical candidates (Anaphylm for anaphylaxis and Libervant for seizures).
What is AQST stock's price target?
This cached page does not contain a precise model fair value for AQST.
Is AQST stock a buy?
The TradeMates model verdict for AQST is HOLD with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.
Is AQST a good dividend stock?
AQST is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.